JP6657196B2 - 線維性疾患などの治療のためのαｖβ６インテグリンアンタゴニストとしてのナフチリジン誘導体 - Google Patents

線維性疾患などの治療のためのαｖβ６インテグリンアンタゴニストとしてのナフチリジン誘導体 Download PDF

Info

Publication number
JP6657196B2
JP6657196B2 JP2017516367A JP2017516367A JP6657196B2 JP 6657196 B2 JP6657196 B2 JP 6657196B2 JP 2017516367 A JP2017516367 A JP 2017516367A JP 2017516367 A JP2017516367 A JP 2017516367A JP 6657196 B2 JP6657196 B2 JP 6657196B2
Authority
JP
Japan
Prior art keywords
methyl
pyrazol
mmol
ethyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017516367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528504A (ja
JP2017528504A5 (enExample
Inventor
ニール、アンドリュー、アンダーソン
イアン、バクスター、キャンベル
マシュー、ハワード、ジェームズ、キャンベル−クロフォード
アシュリー、ポール、ハンコック
セーブル、レンマ
サイモン、ジョン、フォーセット、マクドナルド
ジョン、マーティン、プリチャード
パナヨティス、アレクサンドル、プロコピウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2017528504A publication Critical patent/JP2017528504A/ja
Publication of JP2017528504A5 publication Critical patent/JP2017528504A5/ja
Application granted granted Critical
Publication of JP6657196B2 publication Critical patent/JP6657196B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017516367A 2014-09-26 2015-09-22 線維性疾患などの治療のためのαｖβ６インテグリンアンタゴニストとしてのナフチリジン誘導体 Expired - Fee Related JP6657196B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417094.8A GB201417094D0 (en) 2014-09-26 2014-09-26 Novel compounds
GB1417094.8 2014-09-26
PCT/EP2015/071782 WO2016046230A1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases

Publications (3)

Publication Number Publication Date
JP2017528504A JP2017528504A (ja) 2017-09-28
JP2017528504A5 JP2017528504A5 (enExample) 2018-10-25
JP6657196B2 true JP6657196B2 (ja) 2020-03-04

Family

ID=51901231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516367A Expired - Fee Related JP6657196B2 (ja) 2014-09-26 2015-09-22 線維性疾患などの治療のためのαｖβ６インテグリンアンタゴニストとしてのナフチリジン誘導体

Country Status (12)

Country Link
US (2) US10144733B2 (enExample)
EP (1) EP3197894B1 (enExample)
JP (1) JP6657196B2 (enExample)
KR (1) KR20170053638A (enExample)
CN (1) CN107074851B (enExample)
AU (1) AU2015320863B2 (enExample)
BR (1) BR112017006242A2 (enExample)
CA (1) CA2962321A1 (enExample)
ES (1) ES2811119T3 (enExample)
GB (1) GB201417094D0 (enExample)
RU (1) RU2692775C2 (enExample)
WO (1) WO2016046230A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
JP7034914B2 (ja) * 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
AU2017233739A1 (en) 2016-03-15 2018-09-20 Bayer Cropscience Aktiengesellschaft Substituted sulfonyl amides for controlling animal pests
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
RS63483B1 (sr) 2016-11-08 2022-09-30 Bristol Myers Squibb Co 3-supstituisane propionske kiseline kao inhibitori alfa v integrina
EA201991121A1 (ru) 2016-11-08 2019-11-29 АЗОЛАМИДЫ И АЗОЛАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV
CA3042710A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
SMT202100089T1 (it) * 2016-11-08 2021-03-15 Bristol Myers Squibb Co Pirrol ammidi come inibitori delle integrine alfa v
CN110214137A (zh) 2016-11-08 2019-09-06 百时美施贵宝公司 作为αv整联蛋白拮抗剂的吲唑衍生物
USRE50554E1 (en) 2016-12-23 2025-08-26 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
AU2018229275B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
ES2904645T3 (es) 2017-11-07 2022-04-05 Bristol Myers Squibb Co Derivados de pirrolopirazina como inhibidores de integrina alfa v
CA3109534A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting .alpha.v .beta.6 integrin
WO2020081154A1 (en) * 2018-08-29 2020-04-23 Morphic Therapeutic, Inc. INHIBITORS OF ανβ6 INTEGRIN
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
AU2023232562A1 (en) 2022-03-08 2024-09-05 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
TW202440163A (zh) 2022-12-14 2024-10-16 美商艾拉倫製藥股份有限公司 用於肝外遞送之α－Ｖ β－６（αｖβ６）整合素配體
WO2025259747A2 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2025259743A1 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dual conjugate compounds for extrahepatic delivery

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508323A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
DE69829996T2 (de) 1997-12-17 2006-02-23 Merck & Co., Inc. (A New Jersey Corp.) Integrin-rezeptor-antagonisten
CN1589145A (zh) 1999-06-02 2005-03-02 麦克公司 αv整联蛋白受体拮抗剂
WO2000078317A1 (en) 1999-06-23 2000-12-28 Merck & Co., Inc. Integrin receptor antagonists
EP1229910A4 (en) 1999-10-04 2003-10-01 Merck & Co Inc integrin
YU32502A (sh) 1999-11-08 2004-12-31 Merck & Co.Inc. Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina
US6933304B2 (en) 2000-06-15 2005-08-23 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
JP2004504349A (ja) 2000-07-26 2004-02-12 メルク　エンド　カムパニー　インコーポレーテッド αｖインテグリン受容体拮抗薬
WO2002022616A2 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU2002246757B2 (en) 2001-01-03 2006-02-02 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US20050043344A1 (en) 2002-12-20 2005-02-24 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists derivatives
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
DK2139882T3 (en) 2007-03-23 2014-03-10 Amgen Inc 3-substituted quinoline or quinoxaline derivatives and their use as inhibitors of phosphatidylinositol 3-kinase (PI3K)
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
EP3052515A4 (en) 2013-09-30 2017-03-15 The Regents of the University of California Anti-alphavbeta1 integrin compounds and methods
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
RU2017132433A (ru) 2015-02-19 2019-03-19 Сайфлуор Лайф Сайенсиз, Инк. Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение
JP2018515424A (ja) 2015-03-10 2018-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗アルファｖベータ１インテグリン阻害剤及び使用方法
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
AU2015320863B2 (en) 2018-09-06
US20190048005A1 (en) 2019-02-14
US20170291899A1 (en) 2017-10-12
EP3197894A1 (en) 2017-08-02
WO2016046230A1 (en) 2016-03-31
RU2017114355A3 (enExample) 2019-01-14
JP2017528504A (ja) 2017-09-28
KR20170053638A (ko) 2017-05-16
BR112017006242A2 (pt) 2017-12-12
CA2962321A1 (en) 2016-03-31
CN107074851A (zh) 2017-08-18
CN107074851B (zh) 2020-01-10
EP3197894B1 (en) 2020-06-03
ES2811119T3 (es) 2021-03-10
US10513517B2 (en) 2019-12-24
US10144733B2 (en) 2018-12-04
AU2015320863A1 (en) 2017-03-09
GB201417094D0 (en) 2014-11-12
RU2017114355A (ru) 2018-10-29
RU2692775C2 (ru) 2019-06-27

Similar Documents

Publication Publication Date Title
JP6657196B2 (ja) 線維性疾患などの治療のためのαｖβ６インテグリンアンタゴニストとしてのナフチリジン誘導体
JP6672276B2 (ja) 新規化合物
US10450312B2 (en) Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists
JP6665169B2 (ja) 新規化合物αｖβ６インテグリンアンタゴニスト
US10487080B2 (en) Naphthyridines as integrin antagonists
JP2019509305A (ja) インテグリンアンタゴニストとしてのナフチリジン
HK1214262B (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200205

R150 Certificate of patent or registration of utility model

Ref document number: 6657196

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees